Skip to main content
Caplight Logo









Eleven Therapeutics

Eleven Therapeutics

Private
Tel AvivHealthcare & Life Scienceshttps://eleventx.com

Last Round

Seed

Aug 2, 2022

Total Funding Raised

$22.4M

Company Overview

Eleven Therapeutics operates in Healthcare & Life Sciences and is based in Tel Aviv. Its latest recorded funding round was a Seed round in August 2022.

Eleven Therapeutics is a biotechnology company that develops RNAi therapeutics by combining artificial intelligence, massively parallel functional assays, and combinatorial chemistry.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Eleven Therapeutics Comparables

Compare Eleven Therapeutics with similar companies based on industry and business-model similarity.

Eleven Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Therna Biosciences
83%
Shape Therapeutics
82%
Sail Biomedicines
78%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Eleven Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedAug 2, 2022
GrantDec 18, 2021
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Shaul Ilan

Co-Founder COO & BD

Founding Team

Yaniv E.

Chief Executive Officer

Executive Team

Adi Gilboa-Geffen

Chief Technology Officer

Executive Team

For institutional investors. Book with your work email.

Eleven Therapeutics Investors

Notable investors and investment history

Eleven Therapeutics investors
InvestorRounds
Innovate UKSeed, Grant
NFXSeed
Entrée CapitalSeed
Gates FoundationSeed
Harel Insurance Investments & Financial ServicesSeed
Innovate UKGrant
Entrée CapitalSeed
Book a demo to see all 9 investors

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 2, 2022

    $22M round led by Gates Foundation

  • Dec 18, 2021

    $400K raised from Innovate UK.

Book a demo to see all signals

For institutional investors. Book with your work email.

Recent news

Latest coverage and updates

  • spins_off_companyOct 13, 2026

    Eleven spins off Undecimal, a Cambridge-based spin-out focused on targeted delivery of siRNA therapeutics, on Oct 13th '26.

  • is_developingOct 13, 2026

    In 2022, Eleven raises $22 million in Seed financing, including support from the Bill & Melinda Gates Foundation, to develop small interfering RNA medicines using AI and combinatorial chemistry.

  • receives_financingOct 13, 2026

    Eleven receives $22M in Seed financing in 2022, including support from the Bill & Melinda Gates Foundation, to develop small interfering RNA medicines using AI and combinatorial chemistry.

Book a demo to see all news

For institutional investors. Book with your work email.

Eleven Therapeutics Filings

Explore SEC and related filing metadata, where available.

Eleven Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Eleven Therapeutics's valuation, stock price, and market status.

Is Eleven Therapeutics a public or private company?

Eleven Therapeutics is a private company.

What is the current stock price of Eleven Therapeutics?

Eleven Therapeutics is a private company, so its shares have no public market price. Caplight tracks Eleven Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Eleven Therapeutics worth (valuation)?

Valuation information for Eleven Therapeutics is not publicly available.

Can I buy Eleven Therapeutics stock?

Eleven Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Eleven Therapeutics's last funding round?

Eleven Therapeutics's most recent funding round was Seed on August 2, 2022.

Who are the main investors in Eleven Therapeutics?

Key investors in Eleven Therapeutics include Gates Foundation.

Will Eleven Therapeutics IPO soon?

No public IPO plans have been announced for Eleven Therapeutics.

How can I track Eleven Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades in Eleven Therapeutics's shares on secondary markets.

Firmographic Details

HeadquartersTel Aviv
Employee Range17
Year Founded2020
Last FundingAug 2, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?